Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients

Yana Davidov, Keren Tsaraf, Oranit Cohen‐Ezra, Mariya Likhter, Gil Ben Yakov, Itzchak Levy, Einav G. Levin, Yaniv Lustig, Orna Mor, Galia Rahav, Ziv Ben Ari – 11 November 2021 – The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients.

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1

Juan Yang, Jianming Ye, Tengfei Ma, Fangfang Tang, Li Huang, Zhen Liu, Song Tian, Xu Cheng, Li Zhang, Zhenli Guo, Fuping Tu, Miao He, Xueming Xu, Xiaojuan Lu, Yanyang Wu, Xiaoli Zeng, Jiahua Zou, Xiangcai Wang, Weijie Peng, Peng Zhang – 11 November 2021

A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome

Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee – 11 November 2021

LiverLearning®: 2021 Leon Schiff State-of-the-Art Lecture: Tiny Yet Powerful—Microbes and Their Potential for Treatment of Liver Diseases

Complex multi-directional interactions occur between the gut microbiota and the liver. A disturbance of this delicate homeostasis can contribute to liver disease. Effects of untargeted microbiota therapies including antibiotics, probiotics and fecal microbiota transplantation, have been assessed in clinical trials.  Precision and targeted modifications such as engineered bacteria, postbiotics and phages, can precisely edit the microbiota and modify liver disease progression.

LiverLearning®: 2021 Portal Hypertension: Clinical and Experimental SIG: Controversies in the Screening and Prevention of Clinically Significant Portal Hypertension

This program combines didactic lectures and lively debate to examine controversies in the screening and prevention of clinically significant portal hypertension. Talks cover groundbreaking advances in basic, translational, outcomes, and clinical research in portal hypertension that may be incorporated into clinical practice, along with new pharmacologic interventions to prevent disease progression in these patients.

Subscribe to